Yellow Root - Drug Monograph

> Note to the reader: "Yellow Root" is a vernacular (common) name applied to several botanicals, most commonly Xanthorhiza simplicissima (American yellowroot, shrub yellowroot) and, less frequently, Hydrastis canadensis (goldenseal), Coptis spp. (goldthread), or Berberis spp.. The plants share a common principal constituent — the isoquinoline alkaloid berberine — and a long history of traditional use. This monograph synthesizes the pharmacology of berberine and the available clinical information on X. simplicissima and closely related berberine-containing botanicals commonly sold as "Yellow Root." Yellow Root is regulated in the United States as a dietary supplement, not as an FDA-approved drug, and no formulation is FDA-approved for the treatment of any specific disease.

---

Introduction

Yellow Root is the common name for several berberine-containing medicinal plants of the family Ranunculaceae, with Xanthorhiza simplicissima being the most frequent referent in the eastern United States. Its preparations (decoctions, tinctures, capsules of dried root/rhizome) are used in folk medicine and integrative practice principally for gastrointestinal complaints, mucocutaneous infections, and as a bitter tonic. The clinical relevance of Yellow Root rests almost entirely on the well-characterized pharmacology of berberine and on traditional-use safety signals, because high-quality randomized trials of X. simplicissima itself are sparse.

Drug Class and Overview

• Class: Botanical / herbal medicine (dietary supplement in the U.S.; traditional herbal medicinal product in the E.U.).
• Active constituent class: Isoquinoline alkaloids, principally berberine; Hydrastis additionally contains hydrastine and canadine, which are minor or absent in Xanthorhiza.
• Related berberine-containing botanicals: Hydrastis canadensis (goldenseal), Coptis chinensis / C. japonica (huang lian / goldthread), Berberis vulgaris (barberry), Phellodendron amurense (amur cork tree).
• Distinguishing features: Very high berberine content in the rhizome/root; intense yellow color; broad but modest in vitro antimicrobial and metabolic activity; notable potential for cytochrome P450 and P-glycoprotein interactions.

Mechanism of Action

Berberine, the principal active alkaloid, has multiple molecular targets:

• Antimicrobial: Binds to DNA minor groove and inhibits bacterial RNA polymerase, cell division, and biofilm formation; in vitro activity against Staphylococcus aureus, Streptococcus spp., Helicobacter pylori, Giardia lamblia, Entamoeba histolytica, and certain fungi.
• Metabolic / antihyperglycemic: Activates AMP-activated protein kinase (AMPK) in liver and muscle; inhibits mitochondrial complex I modestly; upregulates insulin receptor expression; reduces hepatic gluconeogenesis.
• Lipid-lowering: Increases LDL-receptor expression via a post-transcriptional mRNA-stabilizing mechanism (mechanism distinct from statins).
• Anti-inflammatory: Inhibits NF-κB activation and downstream cytokines (TNF-α, IL-1β, IL-6); inhibits COX-2 expression.
• Cardiovascular: Vasodilation via endothelial NO; inhibition of platelet aggregation; mild negative inotropy; possible QT prolongation at high concentrations.
• Gastrointestinal: Amoebicidal and antisecretory actions; modulation of gut microbiota.

Indications

Yellow Root is not FDA-approved for any indication. Evidence and traditional use:

• Traditional / folk medicine uses (weak or low-quality evidence): oral decoctions or topical washes for dyspepsia, infectious diarrhea, oral mucositis, mucocutaneous fungal infections, conjunctivitis, and as a uterine tonic.
• Evidence-based uses of berberine (not necessarily of X. simplicissima itself) supported by randomized trials of reasonable quality:
• Adjunctive therapy in type 2 diabetes mellitus (modest HbA1c reduction).
• Hyperlipidemia (modest reductions in LDL-C and triglycerides).
• H. pylori eradication as part of combination regimens.
• Acute infectious diarrhea.
• Unproven / investigational: PCOS, NAFLD, metabolic syndrome, heart failure, arrhythmia, depression, cancer adjunct.

Dosage and Administration

There is no FDA-approved standardized dose for Yellow Root. The following ranges are derived from traditional use and from trials of berberine (often given as the hydrochloride or sulfate salt):

• Traditional decoction of X. simplicissima root: 1–2 g of dried root in 150–250 mL water, simmered 10–15 min, taken 2–3 times daily; not standardized.
• Berberine (the purified alkaloid, used in clinical trials): 500 mg orally 2–3 times daily (total 1.0–1.5 g/day), typically with meals.
• Tincture (1:5, 25% ethanol): 2–4 mL up to three times daily.
• Topical: 1–3% decoction or 0.1–0.2% berberine solution for mucocutaneous use.
• Renal/hepatic impairment: No formal adjustment; use with caution because berberine is metabolized hepatically and may accumulate in hepatic dysfunction.
• Pediatric: Generally avoided in neonates and infants (see Contraindications); pediatric data are limited.
• Geriatric: No specific adjustment; consider lower starting dose and review polypharmacy for interaction risk.
• Pregnancy / lactation: Contraindicated (see below).

Pharmacokinetics

• Absorption: Berberine has very low oral bioavailability (~0.5–5%) due to poor solubility, P-glycoprotein efflux, and extensive first-pass metabolism.
• Distribution: Wide tissue distribution; crosses the blood–brain barrier poorly; concentrates in liver, gut, and certain tumors in animal models. Highly protein-bound.
• Metabolism: Extensive hepatic metabolism via CYP450 (CYP2D6, CYP3A4, CYP2C9, CYP1A2 substrate) and phase II conjugation (glucuronidation, sulfation). Berberine itself also inhibits CYP3A4, CYP2D6, and CYP2C9 and induces CYP1A2 in some models.
• Elimination: Predominantly biliary/fecal; some renal excretion of metabolites.
• Half-life: Reported berberine plasma t½ is variable, generally several hours to ~24 hours depending on formulation; newer phospholipid or phytosome formulations claim improved absorption.

Contraindications

• Pregnancy (uterine stimulation and potential teratogenicity concerns from traditional sources).
• Lactation (alkaloids are secreted in milk; risk of kernicterus-like effects in the neonate).
• Neonates and young infants (immature hepatic conjugation; risk of bilirubin displacement).
• Known hypersensitivity to Xanthorhiza, Hydrastis, Coptis, or other berberine-containing plants.

Warnings and Precautions

• Hepatotoxicity: Rare case reports of elevated transaminases with high-dose or prolonged use; discontinue if jaundice or persistent transaminase elevation occurs.
• Cardiac conduction: Berberine can prolong the QT interval in vitro; caution in patients with congenital long QT, bradyarrhythmias, or those on other QT-prolonging drugs.
• Hypotension / hypoglycemia: Additive effects possible with antihypertensives, vasodilators, and insulin/insulin secretagogues.
• Bleeding risk: Berberine inhibits platelet aggregation; caution perioperatively and with anticoagulants/antiplatelets.
• Neonatal bilirubin displacement: Avoid in the perinatal period.
• Contamination risk: As with all herbal products, variability in alkaloid content, adulteration, and misidentification (e.g., substitution with other "yellow roots") is a documented concern.
• Regulatory: Not evaluated by the FDA for safety or efficacy; manufactured under dietary supplement (DSHEA) regulations in the U.S.

Drug Interactions

Berberine has documented interactions of probable clinical relevance:

• CYP3A4 substrates (inhibition by berberine): Increased levels of cyclosporine, tacrolimus, midazolam, some statins, calcium channel blockers; monitor levels or clinical effect.
• CYP2D6 substrates: Possible increased levels of metoprolol, codeine (reduced conversion to morphine), tricyclic antidepressants, some antipsychotics.
• P-glycoprotein substrates: Increased digoxin and fexofenadine levels have been reported.
• Anticoagulants/antiplatelets (warfarin, DOACs, aspirin, clopidogrel): Additive bleeding risk; monitor INR closely with warfarin.
• Hypoglycemic agents (insulin, sulfonylureas, metformin): Additive glucose lowering; risk of hypoglycemia.
• Antihypertensives: Additive blood-pressure lowering.
• QT-prolonging drugs (amiodarone, sotalol, macrolides, fluoroquinolones, antipsychotics): Additive QT effect.
• Antibiotics (in vitro synergy with some; antagonism reported for others): Caution with co-administration.

Adverse Effects

• Common (mild and dose-related): GI upset, nausea, abdominal cramping, diarrhea or constipation, dyspepsia, bitter taste.
• Occasional: Headache, dizziness, flushing, rash, photosensitivity (rare).
• Serious/rare: Hepatotoxicity, QT prolongation, bradycardia, hypotension, hypoglycemia, neonatal kernicterus, severe drug interactions.
• Frequency data: Not reliably established because clinical trials are heterogeneous and product standardization is variable.

Monitoring Parameters

• Baseline and periodic: Liver function tests (ALT, AST, bilirubin) with chronic use.
• Glycemic monitoring (fasting glucose, HbA1c) when used in patients with diabetes.
• INR when combined with warfarin.
• Drug levels of narrow-therapeutic-index CYP3A4 or P-gp substrates (e.g., cyclosporine, tacrolimus, digoxin).
• ECG in patients with cardiac disease or on QT-prolonging drugs.
• Clinical: Blood pressure, heart rate, signs of bleeding, jaundice, persistent GI symptoms.

Patient Education

• Yellow Root is a dietary supplement, not an FDA-approved medication; it has not been proven to diagnose, treat, cure, or prevent any disease.
• Tell every clinician you see that you are taking Yellow Root, especially before surgery, before starting new prescriptions, or if you become pregnant.
• Avoid in pregnancy and while breastfeeding; do not give to infants or young children.
• Common side effects include stomach upset, diarrhea, and a bitter aftertaste; stop and call your clinician if you develop yellowing of the skin/eyes, dark urine, unusual bleeding or bruising, fainting, or palpitations.
• If you take medicines for diabetes, blood pressure, cholesterol, heart rhythm, blood thinning, or organ transplantation, your clinician may need to monitor you more closely or adjust doses.
• Do not exceed traditional or labeled doses; products vary widely in alkaloid content.

Clinical Pearls

1. "Yellow Root" is a folk name, not a single entity — Xanthorhiza simplicissima, goldenseal, goldthread, and barberry are all sold under this label and share berberine as the principal active alkaloid.
2. Berberine is a multi-target phytochemical: AMPK activation (metabolic), LDL-receptor upregulation (lipid), and broad in vitro antimicrobial activity — but bioavailability is very low and clinical effects are modest.
3. The most clinically important safety concern is drug–drug interaction potential, especially via CYP3A4/2D6 inhibition and P-glycoprotein effects (cyclosporine, tacrolimus, digoxin, warfarin, hypoglycemics).
4. Yellow Root is contraindicated in pregnancy, lactation, and neonates because of risks of uterine stimulation and bilirubin displacement.
5. There is no FDA-approved indication, dose, or standardized extract; treat any product as variable in potency and counsel accordingly.
6. When patients ask about "natural" alternatives to metformin or statins, berberine data are the basis of any evidence-based discussion — but effects are smaller and safety/regulatory oversight is far less than for approved drugs.

References

1. World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1 (includes Hydrastis canadensis and related berberine-containing species). Geneva: WHO; 1999.
2. European Medicines Agency (EMA). Community herbal monograph and assessment report on Hydrastis canadensis L., rhizoma. London: EMA Committee on Herbal Medicinal Products (HMPC); 2010 (and subsequent revisions).
3. National Center for Complementary and Integrative Health (NCCIH). Goldenseal fact sheet for health professionals. U.S. National Institutes of Health. (Reviewed/current version available on the NCCIH website.)
4. American Herbal Products Association. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. Botanical Safety Handbook. 2nd ed. Boca Raton, FL: CRC Press; 2013.
5. Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill; 2023 (chapter on natural products and dietary supplements).
6. Trease and Evans' Pharmacognosy. Evans WC, ed. 16th ed. Edinburgh: Saunders/Elsevier; 2009 (sections on alkaloid-containing Ranunculaceae and berberine-yielding species).
7. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717. (Representative randomized trial of berberine in T2DM.)
8. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine. 2004;10(12):1344–1351.
9. Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytotherapy Research. 2019;33(3):504–523.
10. Cicero AFG, Baggioni A. Berberine and its role in chronic disease. Advances in Experimental Medicine and Biology. 2016;928:27–45. (Springer; review of clinical evidence on berberine in cardiometabolic disease.)
11. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology. 2012;68(2):213–217. (Clinical evidence of CYP3A/CYP2D6 inhibition by berberine.)